Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
Authors:
- Claudia Taborda GómezCGClaudia Taborda Gómez
- Florencia FernándezFFFlorencia Fernández
- Agustín JaraAJAgustín Jara
- Natalia BordaNBNatalia Borda
- Franco MoscoviczFMFranco Moscovicz
- Yessenia Yauri-HuamanYYYessenia Yauri-Huaman
- Rodrigo Caceres-RoblesRCRodrigo Caceres-Robles
- Luis F. Pacheco-OtaloraLPLuis F. Pacheco-Otalora
- Alberto LazarowskiALAlberto Lazarowski
- Jerónimo AuzmendiJAJerónimo Auzmendi
Open Access
- 11 August 2026
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 851
Abstract
Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury, and one of its main characteristics is an increased susceptibility to seizures due to a reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. Methodology. We developed an experimental protocol to discretely measure the seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/every 10 min). Results. Using the DMST, we observed a significant decrease in the seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20 mg/kg) for 14 days following SE. Conclusions. Treatment with CBD did not improve the seizure threshold; moreover, it worsened the hypersensitivity state and delayed recovery following SE. Our results suggest that orally administered CBD, at a human-equivalent therapeutic and safe dose, does not improve susceptibility to seizure development after SE.Keywords
All Related Versions
Funding Information
- National Council for the Science, Technology, and Innovation (PE501082200-2023-PROCIENCIA)
- National Agency for the Promotion of Science and Technology, Fund for Scientific and Technical Research (PICT2019-01282)
This publication has 71 references indexed in Scilit:
- The effects of Cannabidiol on podocytes in vitroBiochemical and Biophysical Research Communications, 2025
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cellsArchives of Toxicology, 2024
- Seizure-mediated iron accumulation and dysregulated iron metabolism after status epilepticus and in temporal lobe epilepsyActa Neuropathologica, 2021
- Cannabidiol Produces Distinct U-Shaped Dose-Response Effects on Cocaine-Induced Conditioned Place Preference and Associated Recruitment of Prelimbic Neurons in Male RatsBiological Psychiatry Global Open Science, 2021
- Effects of acute seizures on cell proliferation, synaptic plasticity and long-term behavior in adult zebrafishBrain Research, 2021
- Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?Epilepsia Open, 2020
- Cannabinoids and EpilepsyNeurotherapeutics, 2015
- Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviourPsychopharmacology, 2011
- Risk of unprovoked seizure after acute symptomatic seizure: Effect of status epilepticusAnnals of Neurology, 1998
- Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic ratsPharmacology Biochemistry and Behavior, 1982